Form 4: Generation Bio Co. Chief Legal Officer Yalonda Howze Granted Stock Options
SEC Form 4 Filing
Yalonda Howze, Chief Legal Officer of Generation Bio Co., was granted stock options to purchase 251,030 shares of common stock on January 10, 2025.
Summary
- Yalonda Howze, the Chief Legal Officer of Generation Bio Co., was granted stock options on January 10, 2025.
- The options allow her to purchase 251,030 shares of Generation Bio Co.'s common stock at an exercise price of $0.926 per share.
- The options vest over four years, with 25% vesting on January 10, 2026, and the remaining shares vesting in equal quarterly installments thereafter.
- The options expire on January 9, 2035.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. It's a neutral-positive event.
Positives
- The grant of stock options aligns the Chief Legal Officer's interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the executive.
Future Outlook
The document does not contain any specific forward-looking statements regarding the company's future performance.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with those of shareholders. The vesting schedule is typical for such grants.
Comparison to Industry Standards
- Stock option grants are a standard component of compensation packages for executives in the biotechnology industry.
- Vesting schedules of four years with a one-year cliff (25% vesting after one year) are common among comparable companies.
- The number of shares granted and the exercise price would be benchmarked against similar roles and company size within the biotech sector.
Stakeholder Impact
- Shareholders may view the stock option grant as a positive incentive for the Chief Legal Officer to contribute to the company's long-term success.
- Employees may see this as a sign of the company's commitment to its leadership team.
Key Dates
| Date | Description |
|---|---|
| 01/10/2025 | Date of earliest transaction (grant date of stock options) |
| 01/10/2026 | First vesting date for 25% of the stock options |
| 01/09/2035 | Expiration date of the stock options |
| 01/14/2025 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.